Showdown over ‘liquid biopsy’ patents lands two cancer test players in court again

Cancer detection test rivals Guardant Health Inc. and Foundation Medicine Inc. are headed back to court over their liquid biopsy technology. Redwood City-based Guardant (NASDAQ: GH) filed a lawsuit Monday in U.S. District Court in Delaware that claims that Foundation, which is owned by Genentech Inc. parent Roche, is infringing on seven patents that are part of Guardant’s intellectual property around using a simple blood draw to identify DNA shed by a tumor. So-called “liquid biopsy” tests…

Click to view original post